Search
for

    Sort by

    Research 30 of 370

    1. Glucagon-Like Peptide-1 Receptor Agonists and Hair Loss: Current Evidence and Potential Mechanisms JAAD reviews. · 2026
    2. The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms Dermatologic Surgery · 2026
    3. Effects of Glucagon-like Peptide-1 Receptor Agonists on Skin Homeostasis and Skin Aging Processes Journal of Clinical Medicine · 2026
    4. Increased Incidence and Risk of Hair Loss with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Multicentre Cohort Study EMJ Dermatology · 2025
    5. Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review Cureus · 2025
    6. Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review Cureus · 2025
    7. Risk of Alopecia Areata with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss medRxiv (Cold Spring Harbor Laboratory) · 2025
    8. Abstract 4142154: Risk of Suicide, Hair Loss, and Aspiration with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS database Circulation · 2024
    9. Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study Journal of the American Academy of Dermatology · 2025 · 31 citations
    10. The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe? Biomolecules · 2025 · 4 citations
    11. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome Hormones · 2015 · 61 citations
    12. Use of Glucagon-Like Peptide-1 (GLP-1) Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review Cureus · 2025
    13. Exploring the hair loss risk in glucagon‐like peptide‐1 agonists: Emerging concerns and clinical implications Journal of the European Academy of Dermatology and Venereology · 2025
    14. Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin Regulatory Peptides · 2006 · 37 citations
    15. Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review Cureus · 2024 · 5 citations
    16. Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes Dermatology and Therapy · 2026
    17. Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons Dermatology and Therapy · 2025 · 1 citations
    18. Effects of GLP ‐1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review International Journal of Dermatology · 2025
    19. Peptide Therapy in Aesthetic, Metabolic, and Endocrine Medicine International Journal of Science and Research (IJSR) · 2026
    20. Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of “Ozempic Face” Dermatology and Therapy · 2026
    21. GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling Science Progress · 2026
    22. GLP-1 Receptor Analogs: Evidence Linking to Effect on Metabolic and Reproductive Functions in Patients with PCOS and Obesity Obesity Facts · 2025 · 3 citations
    23. Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome Therapeutic Advances in Endocrinology and Metabolism · 2019 · 4 citations
    24. Role of Sodium–Glucose Cotransporter-2 Inhibitors in Managing Polycystic Ovary Syndrome: A Systematic Review touchREVIEWS in Endocrinology · 2025 · 2 citations
    25. Management of Hirsutism and Acne in Women with Polycystic Ovary Syndrome: A Narrative Review of Current Evidence and Emerging Therapies Quality in Sport · 2026
    26. Maternal obesity and the metabolic syndrome in reproductive health: assessing incretin-based interventions Reviews in Endocrine and Metabolic Disorders · 2026
    27. INDIVIDUALIZED TREATMENT OF POLYCYSTIC OVARY SYNDROME: A MANIFESTATION-GUIDED PRACTICAL APPROACH Anti-Aging Eastern Europe · 2026
    28. Methylene blue protects hair follicle stem cells from oxidative and metabolic stress to enhance hair regeneration Aging · 2026
    29. Abstracts from the 2024 WDS Forum - virtual option International Journal of Women’s Dermatology · 2025
    30. 74126 GLP-1RA Medications and Alopecia: Evaluating Risk Across Diabetic and Non-Diabetic Populations Journal of the American Academy of Dermatology · 2026